

Penzberg, November 20, 2006

## **Roche Diagnostics` Genome Sequencer 20 System Powers MWG Biotech AG/ Eurofins | Medigenomix Sequencing Service**

Roche Diagnostics has supplied the Genome Sequencer 20 system to Eurofins | Medigenomix / MWG Biotech. Through the purchase of the GS 20 system, Eurofins | Medigenomix / MWG Biotech becomes the first international service provider in Germany to offer their customers access to the next generation of DNA sequencing technology via their production facility in Martinsried. By combining the companies' current sequencing platform, mainly based on Sanger method, and the GS 20 technology, MWG and Medigenomix are able to sequence and compare bacterial genomes in only a couple of days.

MWG Biotech AG, Ebersberg, Germany, has a 10 year experience in worldwide DNA sequencing services. In August 2005, the company joined forces with Eurofins Medigenomix GmbH, Munich, a recognized provider of high quality molecular biology laboratory services.

“As the first sequencing provider in Germany using GS 20 in their own facilities, MWG Biotech AG / Eurofins | Medigenomix will benefit from the systems performance and from its versatility regarding applications, from whole genome sequencing to cancer research,” states Manfred Baier, Head of Roche Applied Science, a business area for Roche Diagnostics. “They make fast sequencing useful for researchers who do not need the full capacity of an own GS 20 system or who do not have all expertise in house, thus further broadening the application field for the system.”

“Being part of the Eurofins Group family, MWG and Medigenomix have the financial capability to invest in state-of-the-art technologies, in order to offer unmatched services to our customers,” informs Bruno Poddevin, Chief Operating Officer, MWG Biotech AG.

And Brigitte Obermaier, Managing Director, Eurofins | Medigenomix, added: “Our agreement and excellent collaboration with Roche Diagnostics will enable a streamlined and smooth integration of the new technology into the existing process workflow.”

Since 2005, the Genome Sequencer 20 System has been available on the sequencing market, setting new standards in velocity and cost-effectiveness for whole genome sequencing, transcriptome analysis, and amplicon sequencing. The system is based on 454 Sequencing™ technology, developed by the US company 454 Life Sciences and can perform sequencing runs up to 60 times faster than conventional commercially available platforms. For preparation of a whole genome, only one single preparation step, without extensive robots for colony picking and handling of the microtiter plates, is needed. One single instrument can produce dozens of megabases of sequence data within a few hours, thanks to parallel-processing, the latest imaging techniques and unique data analysis.

### **About Roche and the Roche Diagnostics Division**

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2005, sales by the Pharmaceuticals Division totalled 27.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.2 billion Swiss francs. Roche employs roughly 70,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our websites [www.roche.com](http://www.roche.com) and [www.roche-diagnostics.com](http://www.roche-diagnostics.com)

### **About MWG Biotech**

MWG Biotech AG, headquartered in Ebersberg, Germany, is an international provider of DNA sequencing services and DNA/siRNA synthesis products for academic and industrial research. With production sites in Germany, the US, and India the company's strength is its strong customer orientation, fast service and high quality products including a series of advanced oligonucleotide and siRNA design tools. For further information, please visit our website [www.mwg-biotech.com](http://www.mwg-biotech.com)

### **About Medigenomix**

Medigenomix GmbH, located in Martinsried, Germany is an innovative bioanalytical company, specialized in services for DNA analysis. The business unit for DNA sequencing and molecular biology applications is well known as outsourcing partner for the biopharmaceutical industry and academic institutions, the unit for Applied Genetics is a leading provider for DNA forensics, paternity testing in humans and animals and authenticity testing in food. A special strength of Medigenomix' team is the extensive experience in purifying and handling DNA samples from different origin for various applications in DNA analysis. For further information, please visit our website [www.medigenomix.com](http://www.medigenomix.com)

### **About Eurofins**

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors. With over 5,000 staff in more than 70 laboratories across 20 countries, Eurofins offers a portfolio of over 15,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff. For further information please visit [www.eurofins.com](http://www.eurofins.com).

For further information please contact:

#### **Roche Diagnostics**

Dr. Burkhard Ziebolz  
[burkhard.ziebolz@roche.com](mailto:burkhard.ziebolz@roche.com)  
+49 621 759 8555

#### **MWG Biotech AG**

Dr. Jutta Huber  
[jhuber@mwgdna.com](mailto:jhuber@mwgdna.com)  
+49 8092 8289 930

#### **Eurofins | Medigenomix GmbH**

Dr. Matthias Pfeiffer  
[pfeiffer@medigenomix.de](mailto:pfeiffer@medigenomix.de)  
+49 89 899892 32